Solid operational growth and improved profitability were achieved in H1 2026, with strong cash flow and robust demand for consumables and equipment. Guidance for full-year revenue and margin was confirmed, despite tariff-related volatility and isolated delays in advanced therapies.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.